benzyl (2R)-4-amino-2-(tert-butoxycarbonylamino)-4-oxo-butanoate | 130539-03-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: benzyl (2R)-4-amino-2-(tert-butoxycarbonylamino)-4-oxo-butanoate
• 英文别名: N-Boc-O-benzyl-D-asparagine；Boc-D-Asn-OBn；benzyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-carbamoylpropanoate；benzyl (2R)-4-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoate
• CAS: 130539-03-6
• 化学式: C₁₆H₂₂N₂O₅
• mdl: MFCD18089443
• 分子量: 322.361
• InChiKey: VNFPRPGXGYMAKL-GFCCVEGCSA-N

物化性质

• 沸点：
  538.6±50.0 °C(Predicted)
• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.437
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzyl (2R)-4-amino-2-(tert-butoxycarbonylamino)-4-oxo-butanoate 在 palladium 10% on activated carbon 、 氢气 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 25.0 ℃ 、103.42 kPa 条件下， 反应 24.0h， 生成 N-myristoyl-D-asparagine
  参考文献：
  名称：

  [EN] CONJUGATES AND METHODS OF USING THE SAME
  [FR] CONJUGUÉS ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2020037009A8
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 potassium carbonate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 5.0h， 生成 benzyl (2R)-4-amino-2-(tert-butoxycarbonylamino)-4-oxo-butanoate
  参考文献：
  名称：

  Comparative Metabolomics and Structural Characterizations Illuminate Colibactin Pathway-Dependent Small Molecules

  摘要：

  The gene duster responsible for synthesis of the unknown molecule "colibactin" has been identified in mutualistic and pathogenic Escherichia coli. The pathway endows its producer with a long-term persistence phenotype in the human bowel, a probiotic activity used in the treatment of ulcerative colitis, and a carcinogenic activity under host inflammatory conditions. To date, functional small molecules from this pathway have not been reported. Here we implemented a comparative metabolomics and targeted structural network analyses approach to identify a catalog of small molecules dependent on the colibactin pathway from the meningitis isolate E. coli IHE3034 and the probiotic E. coli Nissle 1917. The structures of 10 pathway-dependent small molecules are proposed based on structural characterizations and network relationships. The network will provide a roadmap for the structural and functional elucidation of a variety of other small molecules encoded by the pathway. From the characterized small molecule set, in vitro bacterial growth inhibitory and mammalian CNS receptor antagonist activities are presented.

  DOI：

  10.1021/ja503450q

文献信息

• Synthesis of imidazolidin-2-one-4-carboxylate and of (tetrahydro)pyrimidin-2-one-5-carboxylate via an efficient modification of the Hofmann rearrangement
  作者：Gaetano Angelici、Simone Contaldi、Sarah Lynn Green、Claudia Tomasini

  DOI：10.1039/b801909f

  日期：——

  A mild and efficient methodology for the rearrangement of protected asparagine and protected glutamine is reported; good results are obtained with a wide selection of protecting groups.

  报道了一种温和且高效的方法，用于已保护天冬酰胺和已保护谷氨酰胺的重排；在多种保护基团的选择下均取得了良好的结果。
• Peptide nucleic acids (PNAs) with a functional backbone
  作者：Ask Püschl、Stefano Sforza、Gerald Haaima、Otto Dahl、Peter E. Nielsen

  DOI：10.1016/s0040-4039(98)00862-4

  日期：1998.6

  The synthesis of 10 new T-PNA monomers derived from L-amino acids is presented. The monomers were incorporated into decameric PNA oligomers, and the hybridisation with RNA, DNA and PNA complements studied by thermal stability measurements. (C) 1998 Elsevier Science Ltd. All rights reserved.
• US6306892B1
  申请人：——

  公开号：US6306892B1

  公开（公告）日：2001-10-23
• [EN] AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS<br/>[FR] COMPOSÉS INHIBITEURS DE LONP1 CONTENANT DES AMIDES, UTILISATIONS ET PROCÉDÉS
  申请人：[en]PRETZEL THERAPEUTICS, INC.

  公开号：WO2023107481A1

  公开（公告）日：2023-06-15

  Disclosed are compounds according to Formula (1) which inhibit LONP1, and pharmaceutical compositions comprising compounds of the disclosure. Compounds and pharmaceutical compositions of the disclosure may be useful for the treatment of diseases and disorders associated with LONP1, including oncologic diseases and disorders, such as cancer, and diseases and disorders related to mitochondrial dysfunction, such as neurodegenerative disorders, metabolic disorders, and diseases associated with the aging process. The disclosure also relates to methods of using such compounds and compositions for the treatment of such diseases and disorders.